(Q34675482)

3 August 2017

title

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial (English)

1 reference

primary progressive multiple sclerosis

3 August 2017

main subject

phase III clinical trial

0 references

placebo

0 references

0 references

0 references

8

Hans-Peter Hartung

1 reference

3 August 2017

16

Ludwig Kappos

1 reference

3 August 2017

6

Howard Weiner

1 reference

3 August 2017

2

David H Miller

1 reference

3 August 2017

4

Bruce A C Cree

1 reference

3 August 2017

Fred Lublin

1

1 reference

3 August 2017

Mark S Freedman

3

1 reference

3 August 2017

Jerry S Wolinsky

5

1 reference

3 August 2017

Catherine Lubetzki

7

1 reference

3 August 2017

Xavier Montalban

9

1 reference

3 August 2017

Bernard M J Uitdehaag

10

1 reference

3 August 2017

Martin Merschhemke

11

1 reference

3 August 2017

Bingbing Li

12

1 reference

3 August 2017

Norman Putzki

13

1 reference

3 August 2017

Fonda C Liu

14

1 reference

3 August 2017

Dieter A Häring

15

1 reference

3 August 2017

INFORMS study investigators

17

1 reference

3 August 2017

language of work or name

English

0 references

publication date

27 January 2016

1 reference

3 August 2017

1 reference

3 August 2017

volume

387

1 reference

3 August 2017

issue

10023

1 reference

3 August 2017

page(s)

1075-1084

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901314-8

3 August 2017

1 reference

7 January 2021

Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901314-8

7 January 2021

The natural history of primary progressive multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901314-8

7 January 2021

Defining the clinical course of multiple sclerosis: the 2013 revisions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901314-8

7 January 2021

Pathological mechanisms in progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901314-8

7 January 2021

The natural history of primary progressive MS in British Columbia, Canada.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901314-8

7 January 2021

Age at disability milestones in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901314-8

7 January 2021

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901314-8

7 January 2021

Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901314-8

7 January 2021

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901314-8

7 January 2021

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901314-8

7 January 2021

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901314-8

7 January 2021

The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multip

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901314-8

7 January 2021

Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901314-8

7 January 2021

Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901314-8

7 January 2021

Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901314-8

7 January 2021

Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901314-8

7 January 2021

Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901314-8

7 January 2021

FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901314-8

7 January 2021

FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901314-8

7 January 2021

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901314-8

7 January 2021

Bleak prospects for primary progressive multiple sclerosis therapy: downs and downs, but a glimmer of hope

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901314-8

7 January 2021

Quantitative functional measures in MS: what is a reliable change?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901314-8

7 January 2021

Adult norms for the Box and Block Test of manual dexterity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901314-8

7 January 2021

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901314-8

7 January 2021

Accurate, robust, and automated longitudinal and cross-sectional brain change analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901314-8

7 January 2021

Human brain changes across the life span: a review of 56 longitudinal magnetic resonance imaging studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901314-8

7 January 2021

Fingolimod effect on brain volume loss independently contributes to its effect on disability.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901314-8

7 January 2021

10.1016/S0140-6736(15)01314-8

Identifiers

DOI

1 reference

3 August 2017

1 reference